TxCell develops cellular immunotherapy platforms based on antigen-specific regulatory T cells. The Company's products are used for the treatment of severe autoimmune and inflammatory diseases, as well as transplantation-related inflammatory disorders.

Employee Rating

1.0More
TypeSubsidiary
HQValbonne, FR
Founded2001
Websitetxcell.com
TxCell was founded in 2001 and is headquartered in Valbonne, FR

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at TxCell

Stephane Boissel

Stephane Boissel

CEO
Raphael Flipo

Raphael Flipo

SVP, Chief Financial Officer
Francois Meyer

Francois Meyer

Chairman of the Board and Head of Research
Show more

TxCell Office Locations

TxCell has an office in Valbonne
Valbonne, FR (HQ)
Allée de la Nertière
Show all (1)

TxCell Financials and Metrics

Summary Metrics

TxCell Revenue

TxCell's revenue was reported to be €2.23 m in FY, 2017 which is a 24.2% decrease from the previous period.
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.4m4.6m2.9m2.2m

Revenue growth, %

36%(36%)(24%)

General and administrative expense

2.2m3.5m4.5m3.2m

R&D expense

7.8m10.8m10.5m8.5m
Half Year
EURH1, 2015H1, 2016H1, 2017

Revenue

2.0m1.4m1.3m

General and administrative expense

1.9m2.5m1.8m

R&D expense

5.7m5.6m3.9m

Operating expense total

7.6m8.1m5.7m
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.9m9.2m3.5m4.9m

Accounts Receivable

1.0m4.0k4.0k

Current Assets

18.5m13.8m5.8m7.5m

PP&E

1.4m876.0k736.0k625.0k
Half Year
EURH1, 2015H1, 2016H1, 2017

Cash

7.7m3.2m8.7m

Accounts Receivable

233.0k4.0k7.0k

Current Assets

13.3m7.3m11.3m

PP&E

1.3m836.0k631.0k
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.3m)(11.3m)(13.6m)(10.9m)

Depreciation and Amortization

460.0k1.1m(326.0k)272.0k

Accounts Payable

5.8m213.0k(714.0k)(19.0k)

Cash From Operating Activities

(6.9m)(10.1m)(10.4m)(9.8m)
Half Year
EURH1, 2015H1, 2016H1, 2017

Net Income

(5.7m)(7.1m)(5.3m)

Depreciation and Amortization

257.0k(445.0k)107.0k

Accounts Payable

(146.0k)503.0k219.0k

Cash From Operating Activities

(6.3m)(6.1m)(5.1m)
Show all financial metrics

TxCell Operating Metrics

FY, 2015FY, 2016FY, 2017

Patents Licensed

125 200 170
Show all operating metrics

TxCell Online and Social Media Presence

Embed Graph

TxCell News and Updates

Sangamo Therapeutics to Acquire TxCell

RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the ...

TxCell Blogs

Sangamo announces completion of TxCell acquisition

TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. The post Sangamo announces completion of TxCell acquisition appeared first on Txcell.com.

TxCell: financial information for the 3rd quarter of 2018

TxCell today reports its financial information for the 3rd quarter of 2018. The post TxCell: financial information for the 3rd quarter of 2018 appeared first on Txcell.com.

Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares

Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy The post Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares appeared first on Txcell.com.

TxCell terminates its OCABSA financing program following closing of the acquisition by Sangamo of a majority stake in TxCell

The actions provided for by the agreement entered into between TxCell and Yorkville in July 2018 have now been completed as planned. The post TxCell terminates its OCABSA financing program following closing of the acquisition by Sangamo of a majority stake in TxCell appeared first on Txcell.com.

TxCell announces first-half 2018 financial results and update on the proposed acquisition by Sangamo Therapeutics, Inc.

2018 half-year results and update on the proposed acquisition by Sangamo Therapeutics Inc. The post TxCell announces first-half 2018 financial results and update on the proposed acquisition by Sangamo Therapeutics, Inc. appeared first on Txcell.com.

TxCell further improves terms of its OCABSA financing program, subject to closing of its acquisition by Sangamo Therapeutics, Inc.

Agreement for Yorkville to convert the balance of its outstanding OCA at a conversion price of €1.50 per share The post TxCell further improves terms of its OCABSA financing program, subject to closing of its acquisition by Sangamo Therapeutics, Inc. appeared first on Txcell.com.
Show more

TxCell Frequently Asked Questions

  • When was TxCell founded?

    TxCell was founded in 2001.

  • Who are TxCell key executives?

    TxCell's key executives are Stephane Boissel, Raphael Flipo and Francois Meyer.

  • What is TxCell revenue?

    Latest TxCell annual revenue is €2.2 m.

  • Who are TxCell competitors?

    Competitors of TxCell include Bioz, Karius and eGenesis.

  • Where is TxCell headquarters?

    TxCell headquarters is located at Allée de la Nertière, Valbonne.

  • Where are TxCell offices?

    TxCell has an office in Valbonne.

  • How many offices does TxCell have?

    TxCell has 1 office.